Form 8-K - Current report:
SEC Accession No. 0001213900-24-092501
Filing Date
2024-10-31
Accepted
2024-10-31 08:00:10
Documents
15
Period of Report
2024-10-31
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0219313-8k_180life.htm   iXBRL 8-K 31256
2 180 LIFE SCIENCES CORP. PRESS RELEASE DATED OCTOBER 31, 2024 ea021931301ex99-1_180life.htm EX-99.1 14913
  Complete submission text file 0001213900-24-092501.txt   272110

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE atnf-20241031.xsd EX-101.SCH 3787
4 XBRL DEFINITION FILE atnf-20241031_def.xml EX-101.DEF 26629
5 XBRL LABEL FILE atnf-20241031_lab.xml EX-101.LAB 36680
6 XBRL PRESENTATION FILE atnf-20241031_pre.xml EX-101.PRE 25253
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0219313-8k_180life_htm.xml XML 5806
Mailing Address 3000 EL CAMINO REAL BLDG 4, STE 200 PALO ALTO CA 94306
Business Address 3000 EL CAMINO REAL BLDG 4, STE 200 PALO ALTO CA 94306 650-507-0669
180 Life Sciences Corp. (Filer) CIK: 0001690080 (see all company filings)

EIN.: 813832378 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38105 | Film No.: 241412500
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)